Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans

NCT00625014 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Insulin Resistance
Dyslipidemia

Interventions

DRUG: Haloperidol

Sponsor

Leiden University Medical Center

Collaborators

[object Object]